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Abstract. – OBJECTIVE: It is controversial 
whether there is efficacy or safety benefit of epider-
mal growth factor receptor-tyrosine kinase inhib-
itor (EGFR-TKI) in advanced EGFR-mutated non-
small cell lung cancer (NSCLC) compared to stan-
dard chemotherapy. We aim to assess the efficacy 
and safety of EGFR-TKIs compared to another che-
motherapeutics in EGFR-mutated NSCLC.
MATERIALS AND METHODS: Up to April 
27th, 2020, PubMed, Embase, Medline, Scopus, 
Cochrane library, and ClinicalTrials.gov were 
searched for articles or trials meeting the inclu-
sion criteria. After filtering, 230 eligible studies 
were initially identified. Data extraction followed 
PRISMA and included outcomes were progres-
sion-free survival (PFS), overall survival (OS), 
and severe adverse events (SAEs). Direct and 
indirect meta-analyses were generated in the 
context of log-linear mixed-effects models, with 
fixed effects for each relative comparison and 
random effects for each study.
RESULTS: The results showed that EGFR-TKI 
therapy had improved PFS with a hazard ratio 
(HR) of 0.40 (95% CI: 0.36-0.44, p<0.001) com-
pared to standard chemotherapy. Nevertheless, 
the EGFR-TKIs showed no benefit on OS (HR: 
0.96, 95% CI: 0.83-1.10, p=0.556). In the analysis 
of adverse events, EGFR-TKIs had fewer SAEs 
than standard chemotherapy (HR: 0.29, 95% CI: 
0.26-0.33, p<0.001).
CONCLUSIONS: Our systemic review indi-
cates that EGFR-TKI therapy has improved PFS, 
and reduced SAEs compared to standard che-
motherapy in advanced EGFR-mutated NSCLC.
Key Words:
Non-small cell lung cancer, Epidermal growth fac-
tor receptor, Tyrosine kinase, Meta-analysis.
Introduction
Lung cancer has a high incidence globally 
with high cancer-related mortality1. Specifically, 
non-small cell lung cancer (NSCLC) accounts 
for about 85% of all lung cancer and results in 
approximately 1.4 million deaths every year as it 
is often diagnosed at an advanced stage2. 
Epidermal growth factor receptor (EGFR) 
is an oncogene located on chromosome 7p11.2; 
it is one of the most important driver genes in 
lung cancer with activating mutations found 
in up to 20% of NSCLC, mainly adenocarci-
noma. Its mutational status activates tumor 
growth and progression, stimulates cancer cell 
proliferation, invasion, and metastases, and 
inhibits apoptosis3-5. For patients having ad-
vanced NSCLC with activating mutations of 
the EGFR gene, EGFR-tyrosine kinase inhibi-
tor (EGFR-TKI) is the standard treatment. Mul-
tiple randomized controlled trials (RCTs) have 
demonstrated improvement in progression-free 
survival (PFS) when EGFR-TKIs such as gefi-
tinib, erlotinib, afatinib, and Osimertinib were 
compared to platinum-based chemotherapy6-23. 
However, there is controversy regarding 
whether there is an improvement of overall 
survival (OS) for EGFR-TKIs compared to 
standard chemotherapy in advanced EGFR mu-
tated NSCLC. Some meta-analyses, such as 
studies by Guetz et al24 and Lee et al25 did not 
find any OS benefit. However, these meta-anal-
yses used preliminary OS data of large RCTs, 
such as WJTOG3405 by Yoshioka et al7 and 
NEJ002 by Maemondo et al20, thus the results 
might have limited accuracy and have not in-
cluded the most recent data. Another issue is 
that recent meta-analyses comparing the effi-
cacy of EGFR-TKIs with that of chemotherapy 
did not include the results of newly developed 
second- or third-generation EGFR-TKIs, such 
as afatinib25-27. Moreover, quality assessment of 
relevant meta-analyses using the AMSTAR 2 
tool showed that most of these were categorized 
as not having a high methodological quality.
Thus, the primary objective of this study was 
to determine the efficacy and adverse events 
(AEs) of all kinds of EGFR-TKIs, particularly 
including novel drugs, in patients with advanced 
EGFR-mutated NSCLC through meta-analyzing 
all relevant RCTs reporting updated OS data. 
Secondary objective was to test for interactions 
between different EGFR mutation types and oth-
er baseline characteristics that might be associat-
ed with EGFR-TKIs benefit.
Materials and Methods 
Study Eligibility and Identification
Our study was performed according to a 
predefined written protocol registered in PROS-
PERO (CRD42020162429). Two investigators 
searched eligible RCTs independently up to 
April 27th, 2020, using electronic search da-
tabases including PubMed, Embase, Medline, 
Scopus, Cochrane library, and ClinicalTrials.
gov with the following keywords: “non-small 
cell lung cancer” AND “advanced” AND “epi-
dermal growth factor receptor” AND “tyrosine 
kinase inhibitor” AND “randomized controlled 
trials.” We also checked the reference lists of rel-
evant review articles to obtain additional RCTs. 
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Whenever several studies deal with overlapping 
patients, we retained only the final updated ver-
sion as a primary reference to avoid duplication 
of information. 
To be eligible, studies needed to meet all of 
the following criteria: (1) studies should be phase 
III RCTs, (2) patients should be clinically and 
pathologically diagnosed with advanced stage 
(stage IIIB or IV) NSCLC, (3) studies should 
compare EGFR-TKI monotherapy to standard 
first-line chemotherapy, consisting of one or 
more platinum-based therapies, taxanes, or gem-
citabine, (4) EGFR mutation status should be 
available and at least 10 patients per treatment 
group should have EGFR-mutated NSCLC and 
efficacy analyses focus only on patients with 
EGFR-activating mutations, (5) studies should 
report at least one out of PFS, OS, or AEs as 
outcomes, and (6) studies should be published 
either as full-text articles or as informative ab-
stracts. Studies that did not meet all the above 
inclusion criteria were excluded from the me-
ta-analysis. Any disagreements were resolved 
by consensus, including a third author.
Quality Assessment 
Two investigators independently evaluated the 
risk of bias of each eligible study based on the 
criteria described by the Cochrane handbook for 
Systematic Reviews by Cochrane Collaboration28. 
Specifically, we assessed the risk of bias of each 
category, such as random sequence generation, 
allocation concealment, blinding of participants 
and personnel, blinding of outcome assessment, 
incomplete outcome data, selective reporting, and 
other bias into low-risk, high-risk or unclear risk 
constellation. Any disagreements were resolved 
by consensus including a third author.
Data Extraction 
Data selection and extraction were carried out 
by two investigators independently. We record-
ed details of the first author, year of publication, 
number of patients, number of participants with 
EGFR mutations, EGFR-TKI regimens, standard 
chemotherapy regimens, line of treatment, clinical 
data (i.e., EGFR mutation type, smoking history, 
and ECOG score), pathological (i.e. histology), de-
mographic data (i.e., age, sex, ethnicity), treatment 
outcomes (i.e., PFS, OS, AEs, and severe AEs 
[SAEs] that is defined as AE having grade 3 and 
above in the assessment by Common Terminology 
Criteria for Adverse Events), p-value, hazard ratio 
(HR), and 95% confidence interval (CI). Although 
we considered the final updated version as a pri-
mary reference for studies with more than one 
publication, we extracted available data from all 
publications. Any disagreements were resolved by 
consensus, including a third author.
Data Synthesis 
The measure of efficacy and safety was HR 
in overall analysis, but odds ratio (OR) in some 
subgroup analyses. If studies did not report HR, 
we indirectly obtained the HR using the meth-
ods described elsewhere29. Direct and indirect 
meta-analyses were generated in the context of 
log-linear mixed-effects models, similar to the 
model proposed by DerSimonian and Laird with 
fixed effects for each relative comparison and ran-
dom effects for each study30. Heterogeneity across 
studies was tested and partially summarized using 
chi-squared test and I2 statistics as proposed by 
Higgins and Thompson. I2 < 25, 25 ≤ I2 < 50, and 
I2 ≥ 50 were interpreted as signifying low-level, 
intermediate-level, and high-level heterogeneity, 
respectively31,32. AE rates were summarized sep-
arately for each therapy in the context of logistic 
mixed-effects models with a random effect for 
study. For AE summaries, the analyses were based 
on each study’s full safety population, potentially a 
mix of patients with and without EGFR-activating 
mutations. A p<0.05 was considered a statistically 
significant difference. To test publication bias, the 
Egger’s test and Begg’s funnel plots were calcu-
lated using Comprehensive Meta-Analysis version 
333. This same protocol was performed for all sub-
group analyses, which included EGFR-TKI regi-
men, age, smoking status, ECOG status, treatment 
line (first line vs. second line), EGFR mutation, 
histology type, cancer stage, SAEs, and all grades 
of AE.
Ethics and Funding Source 
This study was a literature-based study, and 
as such, no ethics approval was needed. There 
was no funding source associated with the study 
design, collection, analysis, interpretation of the 
data, or writing of the report. All authors had full 
access to all the data.
Results
Overview of Literature Search and 
Study Characteristics
A total of 230 studies were retrieved initially 
for evaluation by identifying references of pre-
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vious meta-analyses and performance of another 
search of the databases from May 1st, 2019 to 
April 27th, 2020. After title and abstract screen-
ing, 41 publications were evaluated in detail. 
Based on the inclusion and exclusion criteria 
described in the methods, a total of 18 RCTs6-23 
comparing the efficacy and toxicity of EGFR-TKI 
monotherapy versus standard chemotherapy were 
finally included in the meta-analysis. The search 
process is described in Figure 1. Table I summa-
rizes the characteristics of the final 18 eligible 
studies.
Progression-Free Survival 
A total of 16 phase III RCTs were includ-
ed for meta-analysis of PFS comparing EG-
FR-TKIs with standard chemotherapy in ad-
vanced EGFR-mutated NSCLC patients. The 
pooling data showed improved PFS with EG-
FR-TKI therapy (HR: 0.40, 95% CI: 0.36-0.44, 
p<0.001), suggesting that EGFR-TKIs have 
PFS advantage compared to standard chemo-
therapy (Figure 2). The test of heterogeneity 
indicated high study-to-study variability with 
Q=48.0 on 15 degrees of freedom (p<0.001) 
and I2 of 68.7%.
Subgroup analyses also demonstrated that EG-
FR-TKIs achieved PFS benefit in all subgroups 
except for NSCLC clinical-stage. For EGFR-TKI 
regimens, the pooled HR for gefitinib versus stan-
dard chemotherapy was 0.410 (95% CI: 0.350-
0.481, p<0.001), erlotinib was 0.406 (95% CI: 
0.229-0.718, p=0.002), and afatinib was 0.405 
(95% CI: 0.198-0.826, p=0.013). Also, regardless 
of gender, smoking status, NSCLC pathologic 
type, EGFR mutational type, ECOG status, and 
treatment line, EGFR-TKI therapy resulted in 
improved PFS compared to standard chemother-
apy in advanced EGFR-mutated NSCLC patients 
(Table II).
Overall Survival
A total of 10 phase III RCTs were included for 
meta-analysis of OS comparing EGFR-TKIs with 
standard chemotherapy in advanced EGFR-mu-
tated NSCLC patients. The pooling data did not 
Figure 1. PRISMA flow chart of 
literature search.
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Table I. Primary characteristics of eligible studies.
   No. of   Treatment EGFR- Median age Men Smoker Hazard ratio
 Author, year Region Patients Intervention Control line mutation (%) (years) (%) (%) (95% CI)*
Ye, 2019 Asia 98 Icotinib Pemetrexed + Cisplatin 1 100 N/A 40.8 24.5 N/A
Yoshioka, 2019 Asia 177 Gefitinib Cisplatin + Docetaxel 1 100 64 30.8 31.4 0.489 (0.336-0.710)
Akamatsu, 2018 Asia 419 Osimertinib Pemetrexed + Carboplatin/ 2, 3, 4 100 62.3 35.8 35.1 0.3 (0.23-0.41)
    Cisplatin
Shi, 2017 Asia 296 Icotinib Cisplatin + Pemetrexed 1 100 56 29.8 21.4 0.61 (0.43-0.87)
Han, 2017 Asia 81 Gefitinib Pemetrexed + Carboplatin 1 100 N/A 43.2 30.1 0.35 (0.21-0.609)
Wu, 2015 Asia 217 Erlotinib Cisplatin + Gemcitabine 1 100 56.8 38.7 29.5 0.43 (0.29-0.64)
Wu, 2014 Asia 364 Afatinib Cisplatin + Gemcitabine 1 100 58 34.7 23.1 0.28 (0.20-0.39)
Kawaguchi, 2014 Asia 301 Erlotinib Docetaxel 2, 3 22 67.5 71.4 74.8 1.22 (0.97-1.53)
Sequist, 2013 International 345 Afatinib Pemetrexed + Cisplatin 1 100 61.3 35.1 31.6 0.58 (0.43-0.78)
Sun, 2012 Asia 135 Gefitinib Pemetrexed 2 46.5 61 14.8 None 0.54 (0.37-0.79)
Rosell, 2012 Europe 174 Erlotinib Cisplatin + Docetaxel/  1 100 65 27.2 30.6 0.37 (0.25-0.54)
    Gemcitabine
Han, 2012 Asia 313 Gefitinib Cisplatin + Gemcitabine 1 44.2 56.8 11.3 None 1.198 (0.944-1.520)
Ciuleanu, 2012 International 424 Erlotinib Pemetrexed + Docetaxel 2 7.7 59 75.7 82.5 1.19 (0.97-1.46)
Zhou, 2011 Asia 165 Erlotinib Carboplatin + Gemcitabine 1 100 57.9 40.9 29.2 0.16 (0.10-0.54)
Maemondo, 2010 Asia 230 Gefitinib Carboplatin + Paclitaxel 1 100 63.3 36.4 38.2 0.322 (0.236-0.438)
Lee, 2009 Asia 313 Gefitinib Cisplatin + Gemcitabine 1 50.9 57 11.3 None 0.737 (0.580-0.938)
Mok, 2009 Asia 1217 Gefitinib Carboplatin + Paclitaxel 1 59.7 57 20.7 6.3 0.74 (0.65-0.85)
Kim, 2008 International 1466 Gefitinib Docetaxel 2, 3, 4 14.8 60.5 65.1 79.7 1.04 (0.93-1.18)
No.: number, N/A: not available, *Hazard ratio for progression-free survival.
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show any OS advantage with EGFR-TKI therapy 
(HR: 0.96, 95% CI: 0.83-1.10, p=0.556). Neither 
EGFR-TKIs nor standard chemotherapy led to an 
OS advantage (Figure 3). The test of heterogene-
ity indicated low study-to-study variability with 
Q=5.27 on 9 degrees of freedom (p=0.810) and 
I2 of 0%.
Subgroup analyses also demonstrated that EG-
FR-TKI therapy did not achieve OS benefit in 
any subgroup. Likewise, regardless of gender, 
smoking status, NSCLC clinical stage, NSCLC 
pathologic type, EGFR mutational type, ECOG 
status, and treatment line, EGFR-TKIs did not 
result in better OS rates than standard chemother-
apy in advanced EGFR mutated NSCLC patients 
(Table II).
Adverse Events
A total of 13 phase III RCTs were included for 
meta-analysis of SAEs comparing EGFR-TKIs 
with standard chemotherapy in advanced EG-
FR-mutated NSCLC patients. The pooled da-
ta showed an SAE advantage with EGFR-TKI 
therapy (HR: 0.29, 95% CI: 0.26-0.33, p<0.001), 
suggesting that EGFR-TKIs cause fewer SAEs 
compared to standard chemotherapy (Figure 4). 
The test of heterogeneity indicated high study-to-
study variability with Q=94.07 on 12 degrees of 
freedom (p<0.001) and I2 of 87.24%.
In subgroup analyses of all grades of AEs, rash 
and diarrhea were more common in EGFR-TKI 
treated patients, while nausea, anorexia, fatigue, 
anemia, and neutropenia were more frequently 
observed in the group receiving standard che-
motherapy. In subgroup analyses of SAEs, EG-
FR-TKIs treated patients showed more frequent 
aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) elevation, rash, and diar-
rhea, while patients treated with standard chemo-
therapy showed more frequent nausea, anorexia, 
fatigue, and neutropenia (Table III). 
Publication Bias
Potential publication bias was evaluated using 
the Egger’s test and Begg’s funnel plots with 
log-transformed HR calculated from prevalence 
rate as the outcome and their standard errors as 
the index for accuracy. The funnel plots of PFS, 
OS, and SAE main findings were symmetrical. 
Funnel plots for subgroup analyses were also 
symmetrical. The data indicates that there is little 
evidence of publication bias.
Figure 2. Forest plot of progression-free survival comparing EGFR-TKI with standard chemotherapy in patients with EGFR 
mutated advanced-stage non-small cell lung cancer.
6238
Table II. Subgroup analyses of progression-free survival and overall survival.
    Progression-Free Survival     Overall Survival
  No. of Effect size  Heterogeneity I2 Egger’s No. of Odds ratio, random  Heterogeneity I2 Egger’s
  Studies (95% CI) p-value (p-value) p-value Studies (95% CI) p-value (p-value) p-value
EGFR-TKI regimen Gefitinib 7 0.410 (0.350-0.481) < 0.001 0% (0.438) 0.790 5 0.975 (0.804-1.182) 0.796 0% (0.526) 0.758
 Erlotinib 5 0.406 (0.229-0.718) 0.002 81.65% (< 0.001) 0.641 4 0.916 (0.693-1.212) 0.540 0% (0.583) 0.608
 Afatinib 2 0.405 (0.198-0.826) 0.013 90.18% (0.001) N/A – – – – –
Gender Male 7 0.474 (0.352-0.638) 0.001 36.20% (0.152) 0.731 3 1.015 (0.701-1.469) 0.937 12.76% (0.318) 0.731
 Female 7 0.341 (0.239-0.487) < 0.001 77.44% (< 0.001) 0.098 3 1.025 (0.810-1.297) 0.835 0% (0.833) 0.762
Age Age < 65 4 0.343 (0.223-0.527) < 0.001 73.79% (0.010) 0.704 – – – – –
 Age ≥ 65 4 0.284 (0.143-0.560) < 0.001 75.07% (0.007) 0.091 – – – – –
Smoking Smoker 6 0.520 (0.333-0.812) 0.004 54.10% (0.054) 0.118 3 0.984 (0.604-1.604) 0.949 39.29% (0.193) 0.428
 Never-smoker 9 0.362 (0.266-0.493) < 0.001 71.46% (< 0.001) 0.508 4 1.025 (0.825-1.273) 0.825 0% (0.931) 0.951
Stage Stage 3B 2 0.492 (0.184-1.319) 0.159 8.23% (0.297) N/A – – – – –
 Stage 4 2 0.343 (0.099-1.188) 0.091 94.46% (< 0.001) N/A – – – – –
Mutation Exon 19 deletion 7 0.284 (0.191-0.423) < 0.001 75.60% (< 0.001) 0.316 3 0.961 (0.678-1.361) 0.822 38.70% (0.196) 0.644
 Exon 21 L858R 7 0.494 (0.373-0.653) < 0.001 45.71% (0.087) 0.339 3 1.101 (0.829-1.460) 0.507 0% (p = 0.973) 0.005
ECOG ECOG 0-1 3 0.329 (0.144-0.753) 0.009 91.71% (< 0.001) 0.114 2 0.896 (0.705-1.139) 0.370 0% (0.964) N/A
 ECOG 2-3 3 0.244 (0.092-0.648) 0.005 0% (0.977) 0.654 2 1.755 (0.671-4.593) 0.251 0% (0.346) N/A
Histologic type Adenocarcinoma 9 0.376 (0.280-0.507) < 0.001 73.61% (< 0.001) 0.466 3 0.969 (0.755-1.243) 0.804 0% (0.999) 0.455
 Non-adenocarcinoma 2 0.237 (0.087-0.645) 0.005 0% (0.848) N/A – – – – –
Treatment line First-line 12 0.397 (0.324-0.487) < 0.001 69.18% (< 0.001) 0.468 8 0.969 (0.842-1.117) 0.667 0% (0.846) 0.825
 Second-line  4 0.464 (0.232-0.926) 0.030 74.28% (0.009) 0.466 2 0.531 (0.188-1.496) 0.231 0% (0.436) N/A
No.: number, N/A: not available, *Hazard ratio for progression-free survival.
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Discussion
NSCLC is a major driver of cancer-associ-
ated mortality. In EGFR-mutated NSCLC, EG-
FR-TKIs are well-tolerated and effective thera-
pies associated with longer PFS times than che-
motherapy6-25. However, whether OS is improved 
with EGFR-TKIs over platinum-based chemo-
therapy remains controversial. Past meta-analy-
ses by Guetz et al.24 and Lee et al.25 demonstrat-
Figure 3. Forest plot of overall survival comparing EGFR-TKI with standard chemotherapy in patients with EGFR mutated 
advanced stage non-small cell lung cancer.
Figure 4. Forest plot of adverse events comparing EGFR-TKI with standard chemotherapy in patients with EGFR mutated 
advanced-stage non-small cell lung cancer.
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ed no OS improvement; both evaluated various 
first-line EGFR-TKIs but were limited by the 
inclusion of more preliminary OS data. Other 
studies by Wu et al26, Li et al27, and Jadad et 
al28 also failed to include more recent therapies 
such as afatinib and osimertinib. Therefore, to 
overcome these methodological challenges, we 
comprehensively analyzed all RCTs to study the 
efficacy of EGFR-TKI monotherapy on PFS and 
OS in EGFR-mutated advanced NSCLC, com-
pared to standard chemotherapy. As the result, 
we analyzed a total of 18 RCTs encompassing 
over 6,000 patients and found that EGFR-TKIs 
offered benefits of risk reduction in disease 
progression and in SAEs compared to standard 
chemotherapy. Benefits to PFS were maintained 
regardless of sex, age, smoking, genetic muta-
tion, ECOG, histologic type, and treatment line 
(first or second). However, EGFR-TKIs were 
not associated with OS benefit, which remained 
across all subgroup analyses. Taken together, 
our study indicates that EGFR-TKIs have a clear 
PFS advantage, but they do not improve OS over 
platinum-based therapy.
It is currently uncertain whether PFS is a valid 
surrogate endpoint for OS in NSCLC. Although 
PFS has been suggested as a valid surrogate 
marker for other cancer types, it has not yet been 
validated in NSCLC34. The US Food and Drug 
Administration recently found a weak associa-
tion between PFS and OS from 14 NSCLC RCTs, 
though this study only reported two trials of first-
line EGFR-TKIs against platinum-based chemo-
therapy35. On the other hand, reliance on OS, par-
ticularly given crossover effects in many RCTs, 
may limit novel therapies having fewer AEs than 
traditional chemotherapy36. Despite several is-
sues, since the care for advanced NSCLC is often 
focused on palliative intent such as an improved 
quality of life and reduction in toxicities, PFS 
benefit may be still an important factor in the 
evaluation and selection of treatment37. 
Of NSCLC driver mutations, EGFR mutations 
are the second most common, with several typical 
mutation locations38. The EGFR gene is located at 
chromosome 7p11.2. The most frequent mutations 
include deletion in exon 19 and L858R mutation 
in exon 21, but multiple other driver mutations 
also exist39. Primary and secondary driver muta-
tions play a role in deciding type of EGFR-TKIs. 
For example, osimertinib is a preferred treatment 
option in patients with EGFR T790M mutations40. 
Table III. Subgroup analyses of all grades and severe adverse events.
 No. of Odds ratio, random  Heterogeneity I2 Egger’s
 studies (95% CI) p-value (p-value) p-value
All grades of AEs  8 0.534 (0.293-0.974) 0.041 48.38% (0.060) 0.158
SAEs* 13 0.314 (0.223-0.446) < 0.001 87.24% (< 0.001) 0.453
All grades of AEs
AST elevation  6 1.828 (0.871-3.840) 0.111 84.85% (< 0.001) 0.744
ALT elevation  8 1.510 (0.978-2.333) 0.063 65.82% (0.005) 0.933
Rash 17 21.79 (13.800-34.396) < 0.001 86.05% (< 0.001) 0.005
Diarrhea 17 5.989 (3.506-10.231) < 0.001 92.30% (< 0.001) 0.022
Stomatitis  8 2.338 (0.864-6.325) 0.094 94.31% (< 0.001) 0.561
Nausea 15 0.115 (0.060-0.220) < 0.001 94.13% (< 0.001) 0.019
Anorexia 13 0.293 (0.178-0.483) < 0.001 90.59% (< 0.001) 0.083
Fatigue 16 0.304 (0.238-0.388) < 0.001 62.68% (< 0.001) 0.815
Anemia 15 0.145 (0.087-0.243) < 0.001 82.68% (< 0.001) 0.014
Neutropenia 16 0.031 (0.020-0.048) < 0.001 66.12% (< 0.001) 0.323
SAEs*
AST elevation  6 4.357 (1.349-14.077) 0.014 37.21% (0.158) 0.663
ALT elevation  7 3.775 (1.397-10.201) 0.009 40.82% (0.119) 0.984
Rash 15 1.755 (0.671-4.593) < 0.001 9.84% (0.343) 0.145
Diarrhea 13 2.258 (1.255-4.064) 0.007 31.62% (0.130) 0.020
Stomatitis  6 1.915 (0.425-8.633) 0.398 43.00% (0.118) 0.175
Nausea 10 0.188 (0.082-0.428) < 0.001 48.88% (0.040) 0.414
Anorexia 11 0.408 (0.185-0.898) 0.026 75.09% (< 0.001) 0.984
Fatigue 13 0.319 (0.187-0.542) < 0.001 55.36% (0.008) 0.356
Neutropenia 16 0.017 (0.011-0.027) < 0.001 24.43% (0.178) 0.997
AEs: adverse events, SAEs: severe adverse events, AST: aspartate aminotransferase, ALT: alanine aminotransferase, *SAEs are 
defined as AEs with grade ≥3.
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On the other hand, the response to treatment is 
not clearly correlated with mutation types. In 
Del19 or L858R mutated NSCLCs, there has been 
uncertainty as to whether one mutation responds 
better to EGFR-TKIs41. Many studies associated 
the Del19 mutation with better outcomes than 
L858R42-44, while other studies report no survival 
differences between mutation types45-47. Del19 
and L858R did not differ with respect to both PFS 
and OS in our study, providing further evidence 
that both mutations are sensitive to EGFR-TKIs 
at similar degrees.
Afatinib and osimertinib, second- and third- 
generation EGFR-TKIs are usually expected 
to be superior to first generation EGFR-TKIs. 
However, in that regard there are no clear evi-
dence yet. The second-generation drug afatinib 
has been suggested to improve PFS and OS over 
platinum-based therapies and older EGFR-TKIs 
in advanced NSCLC by some meta-analyses, but 
not others48-50. Chen et al51 found that osimertinib 
conferred both PFS and OS advantages over plat-
inum-based doublet chemotherapy, though the 
authors disclosed limitations from heterogeneity 
and publication bias. An RCT of second, third, 
and fourth line osimertinib treatment included in 
our analysis described by Akamatsu et al. shows 
PFS benefit compared to standard therapy (HR: 
0.3, 95% CI: 0.23-0.41) but to a similar degree 
as first-generation EGFR-TKIs (HR: 0.40, 95% 
CI: 0.36-0.44). Two RCTs by Wu et al12 in 2014 
and Sequist et al14 in 2013 also demonstrated a 
PFS benefit of afatinib comparable with first-gen-
eration EGFR-TKIs. However, the OS data were 
unavailable for osimertinib and afatinib in our in-
cluded RCTs. Even though osimertinib represents 
one of the most effective EGFR-TKI with the thus 
far longest reported PFS data41, its value for OS 
requires further evaluation.
Besides drug efficacy, AEs are important con-
siderations for cancer treatment. Our study in-
dicates that EGFR-TKI therapy has a benefit of 
fewer SAEs compared to standard chemotherapy. 
Furthermore, the results suggest that EGFR-TKIs 
could be a preferred option for the patients with 
decreased general condition in advanced NSCLC. 
The rates of SAEs for the next-generational drugs 
afatinib and osimertinib were comparable to the 
first-generational EGFR-TKIs.
Our study has several strengths. Indeed, we 
only included RCTs that had already completed 
phase III, allowing for more complete data for 
newer EGFR-TKIs and OS outcomes. Further-
more, studies were largely consistent in using 
EGFR-TKIs as a first- or second-line treatment 
for Del19 or L858R mutated EGFR NSCLCs, 
which reduces the likelihood of introducing 
further heterogeneity in the examined patient 
populations from previous treatment. This 
study also has several limitations. Crossover 
treatment may have been a confounding factor 
even in a number of our included studies7,9,10, 
which may explain the apparent lack of OS 
benefit in our study. Though evidence for bias 
was low, high study heterogeneity in the main 
and subgroup analyses suggest differences in 
experimental design and population character-
istics between studies. Furthermore, most of 
the studies were conducted in Asia, and several 
did not report OS data or rates of SAEs, which 
may cause selection bias and limit relevant 
findings. Subgroup analyses were performed 
without controlling for several clinical pa-
rameters, including ethnicity, metastases, and 
genotype for resistance mutations, which may 
change the interpretation of our findings when 
delivering care. Specifically, the type of EGFR 
mutation, which can impact the efficacy of cer-
tain EGFR-TKIs over others, was not stratified 
in our analyses beyond exon 19 deletions and 
exon 21 L858R mutations. Additionally, OS 
data were limited for analyses for osimertinib 
and afatinib. However, our study contributes to 
increasing evidence that EGFR-TKIs provide 
a longer PFS together with a better toxicity 
profile for patients with advanced EGFR-mu-
tated NSCLC over platinum-based chemother-
apy and therefore supports their use in this 
patient group. Nevertheless, further research 
evaluating afatinib and osimertinib as first-line 
therapies for EGFR-mutated advanced NSCLC 
to confirm OS benefits in combination with 
investigations of treatment sequences based on 
molecular/mutation profiles are warranted. 
Conclusions
Our systematic review with meta-analysis 
demonstrates that EGFR-TKIs induce superior 
PFS in patients with EGFR-mutated advanced 
NSCLC as compared to standard chemotherapy 
but do not improve OS. However, SAEs were also 
reduced in EGFR-TKI treatment relative to stan-
dard chemotherapy. Further studies evaluating 
afatinib and osimertinib as first-line treatments 
for NSCLC are warranted.
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